Key clinical point: Although epidermal growth factor receptor (EGFR)–mutant lung cancers generally don’t benefit from checkpoint inhibitors, there may be some subtypes that do respond.
Major finding: Compared with EGFR wild-type tumors, response rates and overall survival were similar in EGFR L858R cases and reduced in EGFR exon 19 deletion cases.
Study details: A multicenter analysis including 171 EGFR-mutant lung tumors and 212 EGFR wild-type tumors.
Disclosures: The study authors reported disclosures related to Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Calithera Biosciences, Daiichi, Eli Lilly, Novartis, Pfizer, Mirati Therapeutics, Merck, Roche, and Takeda, among others.
Hastings K et al. Ann Oncol. 2019 May 14. doi: 10.1093/annonc/mdz141.